Additional file 1 of Development and clinical evaluation of a rapid antibody lateral flow assay for the diagnosis of SARS-CoV-2 infection

Additional file 1: Fig. S3. Digestionverification of the pET28a-SARS-2-N and pET30a-SARS-2-S1 plasmids. a Plasmid pET28a-SARS-CoV-2-N digestedwith BamH І and Xho І. M: DNA marker. 1: Plasmid pET28a-SARS-CoV-2-N. b Plasmid pET30a-SARS-CoV-2-S1 digestedwith BamH І and Apa І M: DNA marker. 1: Plasmid pET30a-SARS-CoV-2-S1. Fig. S4 Expression and purification of Nprotein and S1 protein of SARS-CoV-2. aSDS-PAGE analysis of N protein showing its expression in E. coli. M: premixed protein marker. 1: protein extracts of uninducedE. Coli. 2: supernatant aftersonication. 3: supernatant after washing pellets with 2 M urea. 4: 8 M ureasolution of the pellet. b SDS-PAGEanalysis of S1 protein showing its expression in E. coli. M: premixed protein marker. 1: protein extracts ofuninduced E. coli. 2: supernatantafter sonication. 3: supernatant after washing inclusion bodies with 2 M urea.4: S1 protein dissolved in 8 M urea. cSDS-PAGE analysis of N protein after purification on the Ni-NTA column. M:premixed protein marker. N: N protein purified on the Ni-NTA column. d SDS-PAGE analysis of purified S1protein. M: premixed protein marker. S1: purified S1 protein after re-folding.